Company news

Curis, Inc. news in 2020

Curis, Inc.'s news releases, calls and decks from 2020, newest first.

View company

Curis Announces Closing of Public Offering of Common Stock with $169.6 Million in Gross Proceeds, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

December 13, 2020

Curis Announces Pricing of Public Offering of Common Stock

December 8, 2020

Curis Announces Proposed Public Offering of Common Stock

December 7, 2020

Curis Announces Positive Preliminary Data from Ongoing Phase 1 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes

December 7, 2020

Curis Announces Updated Preliminary Data from Ongoing Phase 1 Study of CA-4948 Showing Durable and Dose-Dependent Reductions in Tumor Burden in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma

December 6, 2020

Curis Reports Third Quarter 2020 Financial Results

November 9, 2020

Curis Announces Collaboration with the National Cancer Institute for the Development of IRAK4 Inhibitor, CA-4948, as an Anti-Cancer Agent

November 9, 2020

Curis Announces Three Abstracts for CA-4948 Accepted for Presentation at the 62nd American Society of Hematology Annual Meeting and Exposition

November 3, 2020

Curis Reports Second Quarter 2020 Financial Results

August 3, 2020

Curis to Release Second Quarter 2020 Financial Results and Hold Conference Call on August 4, 2020

July 27, 2020

Curis Doses First Patient in Phase 1 Study of CA-4948 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes

July 6, 2020

Curis Announces $17.5 Million Registered Direct Offering

June 10, 2020

Curis Announces FDA Clearance of IND Application for CI-8993, the First-In-Class Monoclonal Anti-VISTA Antibody

June 9, 2020

Curis Reports First Quarter 2020 Financial Results

May 11, 2020

Curis to Release First Quarter 2020 Financial Results and Hold Conference Call on May 12, 2020

May 4, 2020

Curis Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Business Update

March 18, 2020

Curis Announces $30 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC

February 26, 2020

Curis® and DarwinHealth Announce Scientific Collaboration to Characterize Biomarkers and Tumor Subtype Alignments for Fimepinostat in DLBCL and Solid Malignancies

January 12, 2020

Curis Announces Option and License Agreement with ImmuNext for the Development and Commercialization of Anti-VISTA Antibodies

January 6, 2020

Decks in 2020